Back to search results

Observational Study of Anti-VEGF Therapies in Cancer Patients

This observational study looks at complications and how cancer patients respond to anti-VEGF-related therapies. It aims to understand the side effects that may happen to people with advanced cancer receiving these treatments. Researchers will review medical records to see if there's a link between these side effects and how well the treatment works. You may be able to join if you have a hematopoietic and lymphoid cell neoplasm (blood cancer) or a malignant solid neoplasm (solid tumor cancer) and are receiving any anti-VEGF-related treatment. The study is observing side effects for up to 5 years. The current enrollment status is unclear.

Study design
This is an observational study that plans to enroll 170 participants. It is not a treatment study, but rather a review of existing medical records.
What's involved
Your medical records will be reviewed. You will need to understand and sign a consent form.
Compensation
Not stated in the trial record.
Follow-up
The study will observe adverse events for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05108519

Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies

Recruiting
Not specifiedAll AgesObservational
M.D. Anderson Cancer Center
~170 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:Electronic Health Record Review

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of grade 3+ adverse events (AE) at least possibly related to anti-VEGF-related treatment (overall and each type separately)
Measured over Up to 5 years

Conditions

Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT05108519

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • M D Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nicolas L Palaskas · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Nicolas L. Palaskas
[email protected]
713-563-3532
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients must be able to understand and be willing to sign a written informed consent document
Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy

What this trial measures

  • Incidence of grade 3+ adverse events (AE) at least possibly related to anti-VEGF-related treatment (overall and each type separately)Up to 5 years

    For each toxicity, will estimate the odds ratio, associated 95% confidence interval and p-value.